Fer is a nuclear and cytoplasmic intracellular tyrosine kinase. Herein we show that Fer is required for cell-cycle progression in malignant cells. Decreasing the level of Fer using the RNA interference (RNAi) approach impeded the proliferation of prostate and breast carcinoma cells and led to their arrest at the G0/G1 phase. At the molecular level, knockdown of Fer resulted in the activation of the retinoblastoma protein (pRB), and this was reflected by profound hypo-phosphorylation of pRB on both cyclindependent kinase CDK4 and CDK2 phosphorylation sites. Dephosphorylation of pRB was not seen upon the direct targeting of either CDK4 or CDK2 expression, and was only partially achieved by the simultaneous depletion of these two kinases. Amino-acid sequence analysis revealed two protein phosphatase 1 (PP1) binding motifs in the kinase domain of Fer and the association of Fer with the pRB phosphatase PP1a was verified using co-immunoprecipitation analysis. Downregulation of Fer potentiated the activation of PP1a and overexpression of Fer decreased the enzymatic activity of that phosphatase. Our findings portray Fer as a regulator of cell-cycle progression in malignant cells and as a potential target for cancer intervention.
Introduction
Fer is an intracellular tyrosine kinase, which was found to reside in both the cytoplasm and nucleus of mammalian cells (Letwin et al., 1988; Hao et al., 1989; Ben-Dor et al., 1999) . Together with c-Fes, Fer constitutes a distinct subfamily of intracellular tyrosine kinases that share a unique structure. Both kinases bear an extended N-terminal tail that contains an Fps/Fes/ Fer/CIP4 homology domain (FCH), followed by three coiled-coil-forming regions. Whereas the FCH domain could mediate the association of Fer and c-Fes with microtubular structures, the coiled-coil domains were shown to direct the oligomerization of these kinases. The kinase domain of the two enzymes resides at their carboxy-terminal part and is 70% identical in the two proteins (Greer, 2002) .
Fer is activated by growth factors such as epidermal growth factor and platelet-derived growth factor in fibroblastic cells (Kim and Wong, 1998) , and by occupation of the Fcg receptor in mast cells (Penhallow et al., 1995) . Activation of Fer in these systems could be linked to the modulation of cell-cell and cell-substratum interactions, as Fer was shown to associate with and to phosphorylate adherence molecules (Kim and Wong, 1998; Rosato et al., 1998; Craig et al., 2001; Greer, 2002; Kogata et al., 2003; Miravet et al., 2003; Piedra et al., 2003) . Fer was also shown to associate with key cellular regulatory proteins like phosphatidylinositol-3 kinase (Iwanishi et al., 2000) , signal transducer and activator of transcription-3 (Stat3) and with the cytoskeletal linker protein plectin (Lunter and Wiche, 2002) .
Although present in a wide variety of tissues and cells, the functional role of Fer has been elucidated mainly in cells that carry out innate immune response (Greer, 2002; Craig and Greer, 2002) . Interestingly, mice devoid of an active Fer develop normally and the proliferation of fibroblasts derived from these mice is not impaired in vitro (Craig et al., 2001) .
However, several lines of evidence suggest that Fer plays a functional role in the progression and growth of malignant tumors. The kinase was detected in all human malignant cell lines analysed (Hao et al., 1989; Orlovsky et al., 2000) and its levels in malignant prostate tumors are significantly higher than those detected in benign tumors (Allard et al., 2000) . Furthermore, downregulation of Fer impaired the proliferation and abolished the ability of prostate carcinoma PC3 cells to form colonies in soft agar (Allard et al., 2000) . However, the molecular pathways that underlie the function of Fer in malignant cells have not been elucidated. Intervention with the proliferation of malignant cells by the targeting of a single kinase is intriguing considering the redundant cell-cycle regulation in malignant cells (Ortega et al., 2003) . To unravel the mechanisms that underlie the role of Fer in the proliferation of cancer cells, we specifically knocked down Fer in retinoblastoma protein (pRB)-positive malignant cell lines. This revealed a key role of Fer in maintaining G1-S transition during cell-cycle progression in malignant cells.
Results

Downregulation of Fer arrests malignant cells at the G0/G1 phase
To dissect the molecular role of Fer, the cellular level of this kinase was specifically reduced in two malignant cell lines that harbor a functional pRB: PC3, a prostate carcinoma cell line, and MDA-MB-231, a breast carcinoma cell line. The two cell lines were exposed for 72 h to a synthetic double-stranded small interfering RNA (siRNA) directed toward unique 21 nt in the human fer mRNA (Hao et al., 1989) .
In parallel, the cells were treated with a non-relevant siRNA directed toward the luciferase (luc.) mRNA. fersiRNA led to about five and three fold specific decrease in the level of Fer in PC3 and MDA-MB-231 cells, respectively, but did not affect the level of actin, which was used as a control (Figure 1a and c) . Decrease in the level of Fer lowered the number of cells in PC3-and MDA-MB-231-treated cultures by approximately 50 and 40% respectively, as was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (Figure 1b and d) . This could Fer maintains G1-S transition in malignant cells O Pasder et al either result from a diminished viability of the treated cells or could reflect their impaired proliferation rate. Flow-cytometry analysis revealed that whereas luc.-siRNA did not affect the cell-cycle profile of PC3 cells, fer-siRNA increased the percentage of the G0/G1 cells and markedly decreased the percentage of cells residing in the S phase from 19 to 7% (Figure 2a) . However, neither luc.-siRNA nor fer-siRNA significantly affected the percentage of the sub-G0/G1 apoptotic cells in the treated cultures (Figure 2b) . Moreover, annexin V and lactate dehydrogenase assays corroborated the lack of apoptotic or necrotic death induction, in the fer-siRNAtreated cells (data not shown). This implies that depletion of Fer affects the transition of cells from the G1 to the S phase rather than affecting their viability.
To confirm the essential role of Fer in G1-S transition, untreated and siRNA-treated PC3 cells were subjected to bromodeoxyuridine (BrdU) incorporation assay. Whereas the percentage of S phase cells was similar in the untreated and in luc.-siRNA-treated cells, fer-siRNA treatment reduced the percentage of BrdUincorporating cells from 20 to 6% (Figure 2c ). Hence, reduction in the cellular level of Fer interferes with the transition of PC3 cells from the G0/G1 to the S phase. Knockdown of Fer leads to the downregulation of CDK2 in prostate carcinoma cells The arrest of Fer-deprived cells in the G0/G1 phase suggests the involvement of Fer in maintaining or modulating the function of G1-S regulatory proteins. The cellular levels of both negative and positive regulators of G1 progression and G1-S transition (Vermeulen et al., 2003) were therefore determined in untreated and in siRNA-treated cells. PC3 cells were subjected to the fer-siRNA and the levels of early G1 cyclins like cyclin D1, the late G1 cyclin-cyclin E and the S-phase cyclin-cyclin A (Vermeulen et al., 2003) were examined. Of the three cyclins analyzed, only the level of cyclin A was slightly decreased in fer-siRNAtreated cells (Figure 3a) . We also examined the levels of cyclin-dependent kinases (CDKs) that serve as a catalytic constituent of the cyclin/CDK complexes (Vermeulen et al., 2003) . Whereas the levels of CDK4, CDK6 and CDK1 were not changed in cells subjected to fer-siRNA, the level of CDK2 was significantly reduced in PC3 and in another prostate carcinoma cell line DU145, which was subjected to fer-siRNA (Figure 3a and b). Interestingly, the level of CDK2 was not changed in fer-siRNA-treated MDA-MB-231 cells (Figure 3c ). In parallel, the levels of the CDK-activating kinase (CAK) components -CDK7 and cyclin H -were also not affected (Figure 3a) , suggesting a lack of an effect on the functional activation of CDKs (Kaldis, 1999) upon 'knock-down' of Fer. In accordance with this conclusion, we did not see any reduction in the in vitro kinase activity of CDK4 or CDK6 in Fer-depleted cells (data not shown).
The levels of the negative regulators of CDKsp21Cip1 and p27Kip1 (Coqueret, 2003) , were also not altered by the downregulation of Fer (Figure 3a) .
To determine whether Fer regulates the accumulation of CDK2 at the transcriptional or post-transcriptional level, reverse transcription-polymerase chain reaction (RT-PCR) analysis was carried out and the levels of the CDK2 mRNA were determined in luc.-siRNA-and in fer-siRNA-treated cells. This did not reveal a significant Levels of Fer, CDK2 and actin were determined using Western blot analysis. These profiles represent one out of three independent experiments that gave similar results.
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difference between the levels of the CDK2 mRNA in the two analysed samples (Figure 4a ). Furthermore, simultaneous exposure of PC3 cells to both fer-siRNA and the translation inhibitor cycloheximide did not exacerbate the effect of fer-siRNA on the level of CDK2, but rather alleviated this effect ( Figure 4b , lanes 2 and 4). These findings suggest that CDK2 is regulated by Fer at the post-translational level in prostate carcinoma cells.
pRB is hypophosphorylated in fer-siRNA-treated cells CDK2 associates with cyclin E and cyclin A to constitute kinase active complexes during G1-and S-phase progression (Brugarolas et al., 1999) . These two complexes together with CDK4-6/cyclin D1 (Ezhevsky et al., 1997) are engaged in the onset and maintenance of the phosphorylation state of pRB. Phosphorylation of pRB releases E2Fs (Reed, 1997; Yamasaki, 2003) , which in turn activate transcription of genes involved in the onset and regulation of DNA replication (Herrera et al., 1996) . We therefore checked the phosphorylation state of pRB in untreated and in siRNA-treated PC3 and MDA-MB-231 cells. Whereas in untreated and in luc. siRNA-treated cells, unphosphorylated and a pool of phosphorylated pRB forms were clearly detected (Figure 5a ), in fer-siRNA-treated cells, the phosphorylated fraction of pRB (ppRB) was dramatically reduced (Figure 5a ). The nearly complete dephosphorylation of pRB in Fer-depleted PC3 cells indicated that both CDK2 and CDK4/6 sites are dephosphorylated in treated cells. To directly examine this possibility, the phosphorylation levels of several sites were determined. Ser795 is a key regulatory site in pRB (Connell-Crowley et al., 1997) and it is preferentially phosphorylated by CDK4 (Pan et al., 1998) . Thr821, on the other hand, is a preferential CDK2 phosphorylation target (Zarkowska and Mittnacht, 1997) . The phosphorylation levels of these two sites were determined using specific antiphospho antibodies. Whereas the phosphorylation level of these two sites was only slightly changed upon depletion of either CDK4 or CDK2 alone (Figure 5b ), both sites were dephosphorylated in the fer-siRNAtreated cells (Figure 5b ). Moreover, simultaneous depletion of CDK4 and CDK2 affected the phosphorylation level of only Ser795 but not the phosphorylation state of Thr821 ( Figure 5b ). Similarly, knockdown of Fer significantly decreased the phosphorylation level of two other CDK2 phosphorylation sites Ser807 and Ser811 (Connell-Crowley et al., 1997), whose phosphorylation was shown to be necessary for G1-S transition (Brugarolas et al., 1999) (Figure 5c ). To substantiate the pivotal role of Fer in maintaining the phosphorylation state of pRB in malignant cells, a similar analysis was conducted in MDA-MB-231 cells. The phosphorylation levels of Ser780, which is a primary phosphorylation site of CDK4 (Kitagawa et al., 1996) , and of Ser807/811 were examined. Whereas knockdown of Fer significantly affected the phosphorylation states of these CDK4 and CDK2 phosphorylation targets, simultaneous depletion of CDK4 and CDK2 hardly affected the phosphorylation levels of these sites ( Figure 5d ). Interestingly, the phosphorylation levels of Thr821 and Ser795 were not affected by the knockdown of Fer or CDK4 and CDK2 in MDA-MB-231 cells (data not shown), indicating the variations in pRB regulation in different cell types. Hence, downregulation of Fer leads to the hypophosphorylation of pRB.
Knockdown of Fer leads to the hypophosphorylation of PP1a
Maintaining the phosphorylation state of pRB, independently of CDK6, CDK4 and CDK2, implied the involvement of Fer in an alternative pRB regulating pathway. Whereas G1/S CDKs phosphorylate pRB on defined sites (Kitagawa et al., 1996; Connell-Crowley et al., 1997; Zarkowska and Mittnacht, 1997) , the protein phosphatase 1 (PP1) isoforms (Wang et al., 2001) de-phosphorylate these sites in pRB (Rubin et al., 2001) . The balance between these two opposing regulatory mechanisms determines the phosphorylation and activation state of pRB (Berndt et al., 1997) . Phosphorylation of Thr320 in PP1a suppresses the phosphatase activity of that enzyme and increased phosphorylation level of Thr320 is inversely correlated with the phosphatase activity of PP1a in vivo (Dohadwala et al., 1994; Kwon et al., 1997; Liu et al., 1999) . Conversely, dephosphorylation of the Thr320 site induces the phosphatase activity of PP1a toward pRB -siRNA or with fersiRNA in the absence or presence of cycloheximide. Levels of Fer and CDK2 in WCL were determined using Western blot analysis. These data represent one out of three independent experiments that gave similar results.
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O Pasder et al (Berndt et al., 1997) . We therefore examined the phosphorylation state of PP1a on Thr320 in Ferdepleted cells. Knockdown of Fer in PC3 cells did not change the cellular level of PP1a, but led to a profound decrease in the phosphorylation level of PP1a on Thr320 (Figure 6a ). Similarly, knockdown of Fer decreased the phosphorylation level of PP1a in MDA-MB-231 cells (Figure 6b ). To corroborate the regulatory link between Fer and PP1a, a reciprocal experiment was carried out. Hemaglutinin (HA)-tagged Fer (HA-Fer) was stably overexpressed in MCF-7 breast carcinoma cells and the effect of this ectopic expression on the PP1a Thr320 phosphorylation level was examined. Overexpression of Fer upregulated the phosphorylation of PP1a on Thr320 (Figure 6c ), but did not affect the cellular level of PP1a. This implies a regulatory link between Fer and PP1a.
PP1a associates with Fer and is downregulated in Fer-overexpressing cells
The effect of Fer depletion on the activation state of PP1a prompted us to examine a direct interaction between Fer and PP1. The PP1 consensus binding site has been thoroughly characterized in plethora of proteins and was accurately defined (Egloff et al., 1997) . Presence of two PP1 docking motifs was identified in various PP1 binding proteins (Ayllon et al., 2002; Bennett and Alphey, 2002; Sugiyama et al., 2002; Garcia et al., 2003) . Analysis of the murine and human Fer amino-acid sequence revealed the presence of two PP1 docking motifs in the kinase domain of the two kinases and these motifs are separated by 42 aa from each other ( Figure 7a ). As expected, the two PP1 binding motifs are present also in the kinase domain of the meiotic testes specific Fer variant -FerT (Figure 7a ) (Fischman et al., 1990) . were left untreated or were treated with a luc.-siRNA, with a combination of cdk2 and cdk4 siRNAs, with a cdk4-siRNA, with a cdk2-siRNA or with a fer-siRNA. Levels of the indicated proteins or pRB phosphorylation sites were determined using Western blot analysis. The data represent one out of three independent experiments that gave similar results. (d) WCL were prepared from untreated, luc.-siRNA-treated, cdk2 and cdk4-siRNA-treated or fer-siRNA-treated MDA-MB-231 cells. Levels of indicated proteins and pRB phosphorylation sites were determined in a Western blot analysis. The data represent one out of three independent experiments that gave similar results.
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To examine whether Fer and PP1 can indeed associate with each other in vivo, MDA-MB-231 cells were transiently transfected with a vector encoding a Myctagged PP1a catalytic subunit or with the pCMV expression vector alone. Whereas the endogenous Fer co-precipitated with Myc-PP1a from cells expressing the ectopic phosphatase, it was not precipitated by the antiMyc antibody from lysates of cells transfected with the expression vector alone (Figure 7b ). To corroborate this finding, MCF-7 cells stably overexpressing HA-Fer were transiently transfected with the Myc-PP1a encoding vector and Myc-PP1a was immunoprecipitated from cell lysates using anti-Myc antibody. As was found in MDA-MB-231 cells, Fer co-precipitated with the MycPP1a protein (Figure 7c) , implying the association of Fer with PP1a in vivo. To further establish the role of Fer in PP1 regulation, MCF-7 cells were transiently cotransfected with a vector expressing Myc-PP1a together with a vector encoding native HA-Fer, or with a vector encoding a mutated Fer in which a highly conserved phenylalanine residue in one PP1 binding motif (Katayama et al., 2001) was replaced with alanine (HA-FerF606A). This mutation compromised the ability of Fer to bind Myc-PP1a (Figure 7d ) and ectopic expression of the Fer mutant downregulated the phosphorylation of PP1a on Thr320 (Figure 7e ). This decrease was only seen following the expression of the HA-FerF606A mutant but not with the native enzyme (Figure 7e) or with a kinase-inactive Fer mutant, FerY715F, which lacks an autophosphorylation and substrate phosphorylation activity (Ben-Dor et al., 1999; Salem et al., 2005) , but retains the ability to bind PP1 (Figure 7d ). These results corroborate the regulatory link between Fer and PP1.
To examine directly the effect of Fer on the phosphatase activity of PP1a, Myc-PP1a was transiently expressed in MCF-7 cells that ectopically express HAFer and in MCF-7 cells that harbor the expression vector pBabe alone (Figure 8a ). These two cell populations accumulate different levels of Fer (Figure 8a ) but exhibit similar patterns of cell-cycle progression (data not shown). Myc-PP1a was immunoprecipitated from cell lysates and was then subjected to an in vitro phosphatase assay. Incubation of the precipitated enzymes for 90 min in the presence of a synthetic phosphatase substrate revealed a twofold decrease in the phosphatase activity of PP1a that was precipitated from MCF-7-HA-Fer extracts (Figure 8b) . Thus, overexpression of Fer decreases the phosphatase activity of PP1a.
Discussion
G1 progression is a regulatory phase wherein cells respond to and process growth and proliferation stimulatory signaling that lead to G1-S transition (Yamasaki, 2003) . These steps are frequently deregulated in malignant cells and are therefore potential targets for cancer intervening drugs (Vermeulen et al., 2003) . However, recent findings suggested a high functional redundancy of the G1-S regulatory components, like CDK4 and CDK2 (Berthet et al., 2003; Ortega et al., 2003; Tetsu and McCormick, 2003; Malumbres et al., 2004; Sherr and Roberts, 2004) . This new insight raises the need for identification of new regulators of the G1-S transition phase.
In the current work, we showed that decreasing the level of Fer in prostate and breast carcinoma cells, which bear a functional pRB, led to their cell-cycle arrest at the G0/G1 phase. No effect was seen on the percentage of apoptotic cells in the treated cultures. Fer was shown to activate the pro-oncogenic transcription factor Stat3 . However, the essential role of Fer in the currently studied malignant 
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The proliferation arrest of Fer-depleted PC3 and MDA-MB-231 cells resulted most probably from a sustained suppressive activity of pRB (Reed, 1997; Yamasaki, 2003) , whose phosphorylation level (Cheng et al., 1999) was significantly reduced in the treated cells.
Hypophosphorylation of pRB reflected the concomitant dephosphorylation of both CDK4 (Ser795 and Ser780) and CDK2 sites (Ser807, Ser811 and Thr821) in the Fer deprived cells. Interestingly, whereas knockdown of Fer in PC3 cells affected all the analyzed pRB phosphorylation sites, in MDA-MB-231 cells only some of the examined sites (Ser780, Ser807 and Ser811) were affected. This implies a diverse regulation of pRB in different cell types. 
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Depletion of either CDK4 or 2 alone did not significantly affect the phosphorylation state of the pRB target sites. Moreover, simultaneous knockdown of these two key cell-cycle regulators in PC3 cells led to the dephosphorylation of Ser795 in pRB, but did not profoundly affect Thr821, which is a preferential target for CDK2 (Zarkowska and Mittnacht, 1997) . The unchanged phosphorylation level of Thr821 in CDK4/ CDK2-depleted PC3 cells, and of Ser780, Ser807 and Ser811 in CDK4/CDK2-depleted MDA-MB-231 cells, could result from the activity of the CDK1/cyclin A complex, which would compensate for the lack of CDK2/cyclin E and CDK2/cyclin A kinases in these treated cells (Chow et al., 2003) .
Hypophosphorylation on pRB in Fer-depleted cells could result from the malfunctioning of either positive or negative regulators of G1 progression (Cheng et al., 1999) . Of the known pRB regulators that were analysed in this work, only the level of CDK2 was significantly affected by the downregulation of Fer in PC3, and DU145 prostate carcinoma cells. However, the level of CDK2 was not affected in Fer-depleted MDA-MB-231 cells. The level of CDK2 is not significantly changed along the cell cycle (Vermeulen et al., 2003) ; thus, the dependence of the CDK2 level on the presence of Fer is unique and could be specific to prostate carcinoma cells.
Fer was shown to modulate the cytoplasmic and nuclear levels of b-catenin Piedra et al., 2003) , an effect that could link this kinase to the upregulation of the key cell-cycle regulator cyclin D1 (Shtutman et al., 1999; Sellin et al., 2001) . However, the lack of an effect on the level of cyclin D1 in Fer-depleted PC3 cells excludes the role of the b-catenin pathway in mediating the activity of Fer in these cells. Similarly, we did not detect an effect of Fer depletion on the kinase activity of CDK4/cyclin D1 or CDK2/cyclin E complexes (data not shown). This coincides with the lack of a change in the cellular levels of the CDK activators CDK7 and cyclin H (Kaldis, 1999) or the inhibitors p21Cip1 and p27Kip1 (Coqueret, 2003) in Fer-depleted cells.
All these observations prompted us to examine the role of Fer in modulating other activities that directly regulate the functioning of pRB. PP1 is a family of serine/threonine phosphatases that regulate a wide variety of cellular processes. Among these, PP1 activates pRB by removing neutralizing phosphate groups from key regulatory moieties in that tumor suppressing protein (Alberts et al., 1993; Durfee et al., 1993; Ludlow et al., 1993) . Indeed, knockdown of Fer led to the dephosphorylation and activation of PP1a, one of the PP1 variants that were shown to dephosphorylate and activate pRB (Berndt et al., 1997) . The pRB-associated PP1a pool is inactivated by CDK mediated phosphorylation on Thr320 (Liu et al., 1999) and depletion of Fer led to the hypophosphorylation of PP1a on that regulatory site. Conversely, overexpression of Fer increased the phosphorylation of PP1a on Thr320. Thus, Fer sustains the phosphorylation level of PP1a on Thr320, and thereby supports the downregulation of that phosphatase. The ability of Fer to suppress the activity of PP1a was corroborated by the decreased in vitro phosphatase activity of PP1a from Fer-overexpressing cells. This downregulation of PP1a contributes most probably to the neutralization of the pRB suppressive activity, during G1 progression in malignant cells.
The two PP1 docking motifs that were revealed in the kinase domain of Fer most probably mediate the interaction of this kinase with PP1a in vivo. In accordance with this notion, mutation in one of the PP1 binding motifs turned Fer into a dominant-negative mutant that led to a decrease in the phosphorylation level of PP1a. This effect of the HA-FerF606A mutant might be attributed to the ability of an exogenous dominant-negative Fer to form hetero-oligomers with 
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O Pasder et al the endogenous Fer (Craig et al., 2001) and to interfere with its activity (Orlovsky et al., 2000) . The association of Fer with PP1a might enhance the CDK dependent phosphorylation of PP1a on Thr320. Alternatively, Fer could attenuate the auto-or trans-dephosphorylation of PP1a on Thr320 (Dohadwala et al., 1994) . It should be noted that we did not detect tyrosine-phosphorylated PP1a in Fer-expressing cells (data not shown), suggesting that the regulatory effect of Fer on PP1a is kinase activity independent, and may result from the physical interaction between these two proteins. Similarly, Fer binds ERK1/2 and maintains the phosphorylation states of these kinases, independently of the Fer tyrosine kinase activity (Salem et al., 2005) . The functioning of the PP1 phosphatases is regulated by a wide and diverse set of proteins in eucaryotic cells (Ceulemans et al., 2002; Ceulemans and Bollen, 2004) . However, Fer is the first intracellular tyrosine kinase shown to associate with PP1 and modulate its activity. The ability of the Fer kinase to bind and modulate PP1 seems to be harnessed by malignant cells for manipulating the balance between 'signaling' and 'anti-signaling' cascades in which PP1 phosphatases are involved (Honkanen and Golden, 2002) .
Interestingly, unlike in prostate and breast carcinoma cells, the functioning and accumulation level of Fer was found not to be essential in proliferating primary fibroblasts (Craig and Greer, 2002) . Moreover, we failed to detect an interaction between Fer and PP1 in primary mice embryonic fibroblasts (data not shown). This suggests that the regulatory role of Fer in cell-cycle progression might differ between normal and malignant cells. The role of Fer in malignant cells may be related to the tendency of these cells to restrain phosphatase activities in growth-promoting pathways (Honkanen and Golden, 2002) .
Further studies should reveal what other cell-cycle stages are affected by the knockdown of Fer in malignant cells, and whether Fer could serve as a novel intervening target for cancer therapy.
Materials and methods
Preparation of siRNA Double-stranded RNAs, 21 nt long, were synthesized by Dharmacon Research (Lafayette, CO, USA). The targeted sequence was derived from the human fer cDNA (accession no. J03358) 5 0 -AAA GAA ATT TAT GGC CCT GAG-3 0 (nt 84-104 relative to the fer mRNA translation initiation codon). Custom SMART pool siRNA to target the human cdk2 mRNA and the human cdk4 mRNA was purchased from Dharmacon. Selected siRNA sequences were submitted to a BLAST search against the human genome sequence to ensure specificity of the siRNA. A sequence targeting firefly (Photinus pyralis) luciferase (luc.) gene (accession no. X65324) was used as a control.
Cell lines and transfection of cells
Human PC3 and MDA-MB-231 cells were grown at 371C in RPMI and MCF-7 cells were grown in DMEM (GibcoInvitrogen, USA). All growth media were supplemented with 10% fetal calf serum (FCS).
For siRNA transfection, 1.5 Â 10 5 PC3 cells were seeded in 6-cm Petri dish 1 day before transfection. A 30 ml portion of siRNA from 20 mM stock solution was mixed with 300 ml OptiMEM (Gibco-Invitrogen) medium, and then incubated at room temperature for 5 min. A 20 ml portion of Metafectene (Biontex, Germany) was mixed with 160 ml OptiMEM in a separate tube and then incubated at room temperature for 5 min. The two mixtures were then combined, gently mixed and incubated for another 15 min at room temperature, for the formation of lipid-siRNA complexes. Growth medium was removed from the cells, which were then covered with 1290 ml OptiMEM, 200 ml FCS and 510 ml lipid-siRNA mixture. Final siRNA concentration in the Petri dish was 300 nM. After 8 h, 1800 ml OptiMEM and 200 ml FCS were added and cells were harvested 72 h after transfection.
For siRNA transfection, 1.4 Â 10 5 MDA-MB-231 cells were seeded in 6-cm Petri dish 1 day before transfection. OptiMEM (300 ml) was mixed with 30 ml of 20 mM siRNA duplex and with 7 ml of PolyMAG (Magnetofection-Chemicell GmBH, Germany) and the mixture was left for 5 min at room temperature. After addition of 1663 ml OptiMEM, the entire mixture was added to the cells and the culture dish was laid on a manufacturer supplied magnet plate (MagnetoFACTORE plate) for an additional 15 min at 371C. The transfection mixture was then removed and the transfected cells were grown in RPMI supplied with 10% FCS, for 72 h.
For transient overexpression of PP1a, 7 Â 10 5 MDA-MB-231 or 1 Â 10 6 MCF-7 cells were seeded in 10 cm plates 1 day before transfection. Each transfection was performed by mixing 12 mg DNA with 12 ml PolyMAG in 200 ml OptiMEM medium and incubated for 5 min at room temperature. After addition of 5 ml OptiMEM medium, the entire mixture was added to the cells and the culture dish was put on a magnet plate for additional 15 min at 371C. The transfection mixture was then removed and the transfected cells were grown in RPMI supplemented with 10% FCS. Cells were harvested for protein extraction 48 h after beginning of transfection.
For transient overexpression of HA-Fer, HA-FerF606A or pcDNA3 expression vector alone, PC3 cells were seeded in 10 cm plates 1 day before transfection. Each transfection was performed by mixing 15 mg DNA in 1 ml OptiMEM medium and mixture was left for 5 min at room temperature. A 30 ml portion of Lipofectamine 2000 (Invitrogen, USA) was mixed with 1 ml OptiMEM in a separate tube and incubated at room temperature for 5 min. The two mixtures were then combined, gently mixed and incubated for another 30 min at room temperature. After addition of 8 ml OptiMEM medium, the entire mixture was added to the cells for 6 h at 371C. The transfection mixture was then removed and the transfected cells were grown in RPMI supplemented with 10% FCS. Cells were harvested for protein extraction 48 h after beginning of transfection.
MCF-7 cells overexpressing HA-Fer were established as follows: 293T cells were co-transfected with 10 mg pHAFer (Salem et al., 2005) and 10 mg of the pCL-Ampho packaging plasmid (Naviaux et al., 1996) . Production of viruses was performed as described before (Morgenstern and Land, 1990) . For retroviral infection, 2 Â 10 5 MCF-7 cells were seeded in 6 cm plates and were then infected with undiluted 293T supernatants, in the presence of 8 mg/ml polybrene (Sigma, USA) for 6 h. This process was repeated three times in succession, producing an MOI (multiplicity of infection). Two days later, cells were split and selected in puromycin up to a concentration of 2 mg/ml. Cells transfected with the pBabe puro vector alone were used as a control.
For treatment with cycloheximide, PC3 cells transfected with siRNA for 72 h, were subjected to 10 mg/ml cycloheximide for an additional 4 h at the end of the transfection process.
Quantitation of viable cells
Relative number of viable cells in a given culture was determined using the MTT assay. Cultures were assayed for the production of formazan by the reduction of MTT. At 72 h after transfection in 96-well plates, growth medium was removed and cells were incubated for 2 h with 100 ml MTT solution (5 mg/ml MTT dissolved in phosphate-buffered saline (PBS)) at 371C. Cells were then lysed with 50% N,N-dimethyl formamide and the levels of the formazan reduction product were determined by measuring absorbance at 570 nm in a computer-controlled microplate analyser.
Flow-cytometry analysis Cells were rinsed twice with cold PBS, and then harvested by treatment with trypsin. Suspended cells were washed twice in 10 ml cold PBS and centrifuged at 500 Â g for 5 min. The pellet was resuspended in 200 ml cold PBS and cells were stained in the dark with 200 ml propidium iodide (PI) solution (20 mM Tris, pH 8, 1 mM NaCl, 0.1% (v/v) NP-40, 1.4 mg/ml RNase A, 0.05 mg/ml PI) for 30 min at 371C. The total cellular DNA content was determined using a Becton Dickinson flow cytometer (FACSCalibur), Multiple software and ModFit LT software.
BrdU incorporation assay PC3 cells were grown in 6-cm Petri dish and 72 h after transfection with RNAi, were incubated for 30 min with 10 mM BrdU (Boehringer Mannheim, Germany). Incorporation of BrdU was determined using a Becton Dickinson anti-BrdU antibody (347580), according to the manufacturer's protocol. Cells were also stained with 5 mg/ml PI solution. The cellular DNA content was determined using a Becton Dickinson flow cytometer (FACSCalibur) and Multiple software.
Immunoprecipitation
Protein lysates (700 mg) were incubated overnight at 41C with 1:100 diluted anti-c-Myc antibody (13-2500, Zymed, USA). Antigen-antibody complexes were precipitated with protein ASepharose (Amersham Biosciences, UK) after 2 h incubation at 41C. Precipitates were washed three times with TGET buffer (20 mM Tris-HCl, 10% glycerol, pH 7.5, EDTA 1 mM, 0.1% Triton X-100). The first wash was carried out with TGET buffer supplemented with 150 mM NaCl, the second wash was done with TGET containing 75 mM NaCl, and the last wash was with TGET devoid of NaCl.
Western blot analysis WCL were prepared as described before (Salem et al., 2005) . For Western blot analysis, 20-30 mg protein from each sample was resolved in 7-12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Electroblotted proteins were detected using specific anti-Fer antibodies , anti-CDK2 (sc-6248, Santa Cruz, USA), anti-CDK1 (sc-54, Santa Cruz), anti-CDK4 (610148, BD Biosciences, USA), anti-CDK6 (554086, BD Biosciences), anti-CDK7 (sc-856, Santa Cruz), anti-cyclin A (sc-751, Santa Cruz), anti-cyclin D1 (sc-6281, Santa Cruz), anti-cyclin E (sc-247, Santa Cruz), anticyclin H (sc-1662, Santa Cruz), anti-pRB (sc-102, Santa Cruz), anti-phosphosthreonine -pRB (pSer807/811) (9308, Cell Signaling), anti-PP1a (2582, Cell Signaling), anti-PP1 (sc-443, Santa Cruz), anti-phosphothreonine 320 -PP1a (pThr320) (2581, Cell Signaling), anti-p21Cip1 (sc-6246, Santa Cruz), anti-p27Kip1 (sc-528, Santa Cruz), anti-HA (NMS-101R, Covance, USA), anti-Myc (13-2500, Zymed) and anti-actin antibody (A 4700, Sigma). Bound antibodies were visualized using chemiluminescence reaction (Pierce, USA). The blots were scanned using an optical scanner (Umax Astra 3400) and the optical density of each band was compiled using the ImageJ software application.
Quantitative RT-PCR analysis Whole-cell RNA was extracted from PC3 cells using TRI Reagent (Molecular Research Center, ICN, USA) following the manufacturer's instructions. Total RNA (25 ng) was reverse-transcribed using AccessQuick RT-PCR System (Promega, USA) with specific oligonucleotides derived from the human CDK2 mRNA: forward primer 5 0 -CTA GCT TTC TGC CAT TCT CAT C-3 0 and reverse primer 5 0 -GAA GAG CTG GTC AAT CTC AGA A-3 0 . The selected primers are derived from separated exons (4 and 6), which flank an intron of the CKD2 gene. PCR was run for 27 cycles, which was found to be optimal for quantitative comparison of the CDK2 mRNA levels. The expected 275-bp-long PCR product is specific to the mature CDK2 mRNA, and can be differentiated from a contamination of genomic DNA PCR products. 18S ribosomal RNA primer pairs (Quantum RNA, Ambion, USA) were used to yield a 489 bp fragment derived from the 18S rRNA (ribosomal RNA) as an internal control. PCR products were separated in 1.4% agarose gel and visualized with ethidium bromide.
Construction of plasmids
The pCMV-c-Myc-PP1a expression plasmid was constructed by amplifying a human PP1a cDNA clone (RZDP-IRAUp969F0224D) with a forward primer 5 0 -AACCCGA ATTCTGTCCGACAGCGAGAAGC-3 0 , which bears at its 5 0 -end an EcoR1 site, and a backward primer 5 0 -AAGGAC TCGAGCTATTTCTTGGCTTTGGCGG-3 0 , which bears an Xho1 site at is 3 0 end. The amplified fragment was cloned into an EcoR1-Xho1 cut pCMV-c-Myc vector (BD Clonetech Inc., USA).
Mutated Fer (FerF606A) was constructed by 'site-directed mutagenesis' method as follows. Phe 606 was changed to Ala as follows: primers A and B are reverse complement primers that contain the mutated residue: A, 5 0 -AAAATAAAGGCTCTA CAGGAAGC-3 0 ; and B, 5 0 -GCTTCCTGTAGAGCCTT TATTTT-3 0 . Primers C and D are the external 5 0 and 3 0 primers designed for the amplification of the mutated cDNA portions: C, 5 0 -GCATGACTGGTACCATGGTG-3 0 ; and D, 5 0 -TTCTTGCTCTCGAGATACAACA-3 0 . The two overlapping cDNA portions were separately amplified from a murine fer-cDNA and were than mixed, denatured and allowed to complete a mutated double-stranded fragment using Pfu Ultra DNA polymerase. The obtained mutated fer fragment was then amplified and cloned into a corresponding fer-cDNA to give rise to a mutated FerF606A.
In vitro phosphatase assay MCF-7 cells overexpressing HA-Fer or harboring the retroviral vector pBabe as control were transiently transfected with a Myc-PP1a expression vector. WCL were prepared from the cells 48 h after transfection in a lysis buffer that lacked phosphatase inhibitors. Myc-PP1a was immunoprecipitated from 1 mg lysate with anti-c-Myc antibody as described above. The immunoprecipitated Myc-PP1a was rinsed twice with buffer A (50 mM Tris-HCl, 5% glycerol, 50 mM NaCl, 1 mM dithiothreitol, 1 mM MgCl 2 , 3mM MnCl 2 ). The immune complexes (each containing 150 ng protein) were then suspended in a phosphatase activity buffer (buffer A containing 0.1 mg/ml purified BSA) and were then incubated at 301C in the presence of the synthetic substrate 5 mM pNPP disodium hexahydrate (Sigma). Dephosphorylation of the substrate was quantitated by measuring absorbance at 405 nm in a computer-controlled microplate analyser.
